RightFit
RecruitingNot applicable

HEME Home Transfusion Program

Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests a program that offers blood transfusions at home during hospice care, compared with usual care. It is for adults with blood cancer that has come back or has not responded to treatment, who are expected to live six months or less. The study looks at quality of life, mood, and use of health care near the end of life.

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Patients: Have blood cancer that has come back or has not responded to treatment.
  • Patients: Are age 18 or older.
  • Patients: Get their main cancer care at DFCI and had at least 2 clinic visits there in the past 12 months.
  • Patients: Have had at least one red blood cell or platelet transfusion in a clinic or hospital since their blood cancer diagnosis, without a severe reaction. Platelets help blood clot.
  • Patients: Live in the area served by Care Dimensions Hospice.
  • Patients: Have a doctor who expects them to live six months or less.
  • Caregivers: Are an identified informal caregiver for a patient enrolled in the study.
  • Caregivers: Are age 18 or older.

Who can't join

  • Patients: Are younger than 18.
  • Patients: Are already enrolled in hospice.
  • Patients: Live in a nursing home or assisted living facility.
  • Patients: Have had a serious reaction to a blood transfusion.
  • Caregivers: Are younger than 18.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria for Patient Participants: * Diagnosis of a relapsed/refractory hematologic malignancy * Age ≥ 18 years * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment) * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction * Patient resides within catchment served by Care Dimensions Hospice * Physician-estimated prognosis of six months or less Inclusion Criteria for Caregivers: * Identified informal caregiver of enrolled patient with hematologic malignancy * Age ≥ 18 years Exclusion Criteria for Patient Participants: * Age \< 18 years * Already enrolled in hospice * Resides in nursing home or assisted living facility * History of previous serious adverse transfusion reaction Exclusion Criteria for Caregivers: -Age \< 18 years

Study sites (2)

MA